NO974685L - Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse - Google Patents

Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse

Info

Publication number
NO974685L
NO974685L NO974685A NO974685A NO974685L NO 974685 L NO974685 L NO 974685L NO 974685 A NO974685 A NO 974685A NO 974685 A NO974685 A NO 974685A NO 974685 L NO974685 L NO 974685L
Authority
NO
Norway
Prior art keywords
processes
preparation
pharmaceutical compositions
compositions containing
acetamide derivatives
Prior art date
Application number
NO974685A
Other languages
English (en)
Other versions
NO310619B1 (no
NO974685D0 (no
Inventor
Teruya Murata
Katsuhiko Hino
Makato Oka
Mari Itoh
Kiyoshi Furukawa
Original Assignee
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co filed Critical Dainippon Pharmaceutical Co
Publication of NO974685D0 publication Critical patent/NO974685D0/no
Publication of NO974685L publication Critical patent/NO974685L/no
Publication of NO310619B1 publication Critical patent/NO310619B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO19974685A 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse NO310619B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11393795 1995-04-13
PCT/JP1996/000977 WO1996032383A1 (fr) 1995-04-13 1996-04-10 Derives de l'acetamide, procede de fabrication et composition medicamenteuse a base de ces derives

Publications (3)

Publication Number Publication Date
NO974685D0 NO974685D0 (no) 1997-10-10
NO974685L true NO974685L (no) 1997-12-12
NO310619B1 NO310619B1 (no) 2001-07-30

Family

ID=14624947

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19974685A NO310619B1 (no) 1995-04-13 1997-10-10 Acetamidderivater og farmasöytisk preparat inneholdende disse

Country Status (25)

Country Link
US (1) US5972946A (no)
EP (1) EP0826673B1 (no)
KR (1) KR100433589B1 (no)
CN (1) CN1094929C (no)
AR (1) AR002289A1 (no)
AT (1) ATE228113T1 (no)
AU (1) AU694647B2 (no)
BR (1) BR9604894A (no)
CA (1) CA2218033A1 (no)
CZ (1) CZ289093B6 (no)
DE (1) DE69624916T2 (no)
DK (1) DK0826673T3 (no)
ES (1) ES2187644T3 (no)
HU (1) HUP9801688A3 (no)
IL (1) IL117659A (no)
NO (1) NO310619B1 (no)
NZ (1) NZ304982A (no)
PL (1) PL322819A1 (no)
PT (1) PT826673E (no)
RO (1) RO117532B1 (no)
RU (1) RU2160256C2 (no)
SK (1) SK281840B6 (no)
TW (1) TW450963B (no)
WO (1) WO1996032383A1 (no)
ZA (1) ZA962438B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221855B1 (hu) * 1994-09-09 2003-02-28 Nippon Shinyaku Co., Ltd. Szubsztituált piridin-, pirimidin- és triazinszármazékok és ilyen vegyületeket tartalmazó gyógyászati készítmények
DK1004573T3 (da) 1997-08-04 2003-03-03 Nihon Nohyaku Co Ltd Aryloxyanilinderivater
AU749214C (en) 1997-11-21 2006-03-30 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
WO1999058117A1 (fr) * 1998-05-13 1999-11-18 Sanofi-Synthelabo Utilisation de composes reduisant l'apoptose
FR2778564B1 (fr) * 1998-05-13 2001-07-13 Sanofi Sa Utilisation de composes reduisant l'apoptose
JP2002241369A (ja) * 1998-05-18 2002-08-28 Dainippon Pharmaceut Co Ltd ４−ピリミジニルアミノアセトアミド誘導体及びそれを含有する医薬組成物
DE19853278A1 (de) 1998-11-19 2000-05-25 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-cyclopenta[d]pyrimidine, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
EP1607744A3 (en) * 1998-12-18 2009-09-30 Scios Inc. Treatment of diseases involving cyst formation with combinations comprising a PTBR agonist
ES2268894T3 (es) 1998-12-18 2007-03-16 Scios Inc. Agonistas y antagonistas de receptores de benzodiazepina de tipo periferico.
US6380183B1 (en) 1998-12-18 2002-04-30 Scios, Inc. Treatment of diseases involving cyst formation
DE60043692D1 (de) 1999-01-22 2010-03-04 Elan Pharm Inc Acyl derivate zur behandlung von krankheiten die in zusammenhang mit vla-4 stehen
CA2359112A1 (en) 1999-01-22 2000-07-27 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by vla-4
DE60021251D1 (de) 1999-01-22 2005-08-18 Elan Pharm Inc Multizyklische verbindungen zur hemmung der durch vla-4 vermittelten leukozytenadhäsion
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
DE19904710A1 (de) * 1999-02-05 2000-08-10 Aventis Pharma Gmbh Substituierte 4-Amino-2-aryl-tetrahydrochinazoline, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
CA2361162A1 (en) 1999-03-01 2000-09-08 Elan Pharmaceuticals, Inc. Alpha-aminoacetic acid derivatives useful as alpha 4 beta 7-receptor antagonists
US7037916B2 (en) * 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
US6620817B1 (en) 1999-11-17 2003-09-16 Dainippon Pharmaceutical Co., Ltd. [5-chloro-6-phenyl-2-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal compositions containing the same and intermediate of these compounds
CA2373411A1 (en) * 2000-03-16 2001-09-20 Taeyoung Yoon 5-substituted arylpyrimidines
US6943173B2 (en) 2000-07-18 2005-09-13 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
ATE326458T1 (de) * 2000-09-15 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1698627A1 (en) * 2000-09-15 2006-09-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ZA200301701B (en) * 2000-09-15 2004-03-01 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors.
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1353916T3 (da) * 2000-12-21 2007-01-29 Vertex Pharma Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer
AU2002364536B2 (en) * 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
SG159380A1 (en) * 2002-02-06 2010-03-30 Vertex Pharma Heteroaryl compounds useful as inhibitors of gsk-3
AU2003215379A1 (en) * 2002-02-22 2003-09-09 Pharmacia And Upjohn Company Substituted pyrimidinones and pyrimidinthiones
US20040009981A1 (en) * 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
CN101037438A (zh) 2002-08-02 2007-09-19 沃泰克斯药物股份有限公司 用作gsk－3的抑制剂的吡唑组合物
KR20110010824A (ko) 2003-01-14 2011-02-07 아레나 파마슈티칼스, 인크. 대사 조절제로서의 １,２,３-삼치환된 아릴 및 헤테로아릴 유도체, 및 당뇨병 및 고혈당증을 비롯한 이에 관련된 장애의 예방 및 치료
US7601718B2 (en) * 2003-02-06 2009-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
PE20050355A1 (es) * 2003-08-05 2005-05-16 Vertex Pharma Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
US7378409B2 (en) * 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
CN1922141A (zh) * 2004-02-23 2007-02-28 大日本住友制药株式会社 新的杂环化合物
GT200600005A (es) * 2005-01-12 2006-08-16 Un derivado de 2-(aminocarbonilo ciclico)-indolina y una composicion farmaceutica que lo contiene
AU2006279376B2 (en) * 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
JP5101512B2 (ja) 2005-09-29 2012-12-19 エラン ファーマシューティカルズ，インコーポレイテッド Ｖｌａ−４によって媒介される白血球接着を阻害するピリミジニルアミド化合物
CN101273035A (zh) 2005-09-29 2008-09-24 伊兰制药公司 抑制由vla-4介导的白细胞粘附的氨基甲酸酯化合物
NZ594385A (en) * 2005-11-03 2013-02-22 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
WO2007054453A2 (en) * 2005-11-11 2007-05-18 F. Hoffmann-La Roche Ag Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
NZ570679A (en) 2006-02-27 2011-01-28 Elan Pharm Inc Pyrimidinyl sulfonamide compounds which inhibit leukocyte adhesion mediated By VLA-4
CN102516161A (zh) * 2006-03-29 2012-06-27 弗·哈夫曼-拉罗切有限公司 作为mGluR2拮抗剂的吡啶和嘧啶衍生物
MX2009004807A (es) * 2006-11-02 2009-06-15 Vertex Pharma Aminopiridinas y aminopirimidinas utiles como inhibidores de proteina cinasa.
DE602007007985D1 (de) * 2006-12-19 2010-09-02 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyrimidine
EP1941879A1 (en) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Neuroprotective agent for the treatment of neuronal damage
AU2008226466B2 (en) * 2007-03-09 2013-06-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
JP5520057B2 (ja) * 2007-03-09 2014-06-11 バーテックス ファーマシューティカルズ インコーポレイテッド 蛋白キナーゼの阻害剤として有用なアミノピリミジン
MX2009010127A (es) * 2007-03-22 2009-11-05 Vertex Pharma Compuestos utiles como inhibidores de janus cinasas.
CN101679386A (zh) 2007-04-13 2010-03-24 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
AU2008247594A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP5572087B2 (ja) * 2007-05-02 2014-08-13 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼ阻害として有用なアミノピリミジン
EP2152694A2 (en) * 2007-05-02 2010-02-17 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
AU2008257044A1 (en) * 2007-05-24 2008-12-04 Vertex Pharmaceuticals Incorporated Thiazoles and pyrazoles useful as kinase inhibitors
EP2176261B1 (en) * 2007-07-31 2012-12-19 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
TWI378096B (en) 2008-06-19 2012-12-01 Takeda Pharmaceutical Heterocyclic compound and use thereof
JP2012501971A (ja) * 2008-09-03 2012-01-26 バーテックス ファーマシューティカルズ インコーポレイテッド 共結晶および共結晶を含む薬学的処方物
WO2010068794A2 (en) 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
SG175355A1 (en) * 2009-04-27 2011-12-29 Elan Pharm Inc Pyridinone antagonists of alpha-4 integrins
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
GB0913636D0 (en) 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
JP2013032290A (ja) * 2009-11-20 2013-02-14 Dainippon Sumitomo Pharma Co Ltd 新規縮合ピリミジン誘導体
BR112013008100A2 (pt) 2010-09-22 2016-08-09 Arena Pharm Inc "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles."
WO2012065963A2 (en) 2010-11-15 2012-05-24 Katholieke Universiteit Leuven Novel antiviral compounds
EP3242666A1 (en) 2015-01-06 2017-11-15 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
KR20230160955A (ko) 2015-06-22 2023-11-24 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631045A (en) * 1969-11-04 1971-12-28 American Home Prod 4 5-diamino-7h-pyrrolo(2 3-d)pyrimidine derivatives
US3631036A (en) * 1969-11-04 1971-12-28 American Home Prod 5-amino-2 6-substituted-7h-pyrrolo(2 3-d) pyrimidines and related compounds
FR2263750A1 (en) * 1974-03-12 1975-10-10 Delalande Sa N-phenyl-N-(2-aryl-6-methyl-pyrimidin-4-yl)amino acid derivs. - useful e.g. as analeptics, hypotensives, analgesics, etc.
FR2525595A1 (fr) * 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2582514B1 (fr) * 1985-05-30 1988-02-19 Rhone Poulenc Sante Medicaments a base d'amides, nouveaux amides et leur preparation
DK273689A (da) * 1988-06-06 1989-12-07 Sanofi Sa 4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
JPH07165721A (ja) * 1993-12-15 1995-06-27 Sumitomo Chem Co Ltd 放射性イソキノリンカルボキサミド誘導体

Also Published As

Publication number Publication date
NO310619B1 (no) 2001-07-30
CZ322397A3 (cs) 1998-02-18
SK281840B6 (sk) 2001-08-06
DK0826673T3 (da) 2003-03-24
ATE228113T1 (de) 2002-12-15
SK137497A3 (en) 1998-05-06
HUP9801688A2 (hu) 1999-03-29
CZ289093B6 (cs) 2001-10-17
CN1094929C (zh) 2002-11-27
HUP9801688A3 (en) 2001-11-28
WO1996032383A1 (fr) 1996-10-17
NO974685D0 (no) 1997-10-10
ES2187644T3 (es) 2003-06-16
AU694647B2 (en) 1998-07-23
EP0826673B1 (en) 2002-11-20
US5972946A (en) 1999-10-26
RO117532B1 (ro) 2002-04-30
AU5287496A (en) 1996-10-30
ZA962438B (en) 1996-10-01
AR002289A1 (es) 1998-03-11
PL322819A1 (en) 1998-02-16
DE69624916D1 (de) 2003-01-02
IL117659A0 (en) 1996-07-23
PT826673E (pt) 2003-02-28
IL117659A (en) 2000-12-06
TW450963B (en) 2001-08-21
CN1186487A (zh) 1998-07-01
EP0826673A4 (en) 1998-09-02
BR9604894A (pt) 1998-07-14
DE69624916T2 (de) 2003-04-24
CA2218033A1 (en) 1996-10-17
KR100433589B1 (ko) 2004-09-13
NZ304982A (en) 1999-03-29
EP0826673A1 (en) 1998-03-04
RU2160256C2 (ru) 2000-12-10
KR19980703815A (ko) 1998-12-05

Similar Documents

Publication Publication Date Title
NO974685L (no) Acetamidderivater, fremgangsmåte for fremstilling av disse, og farmasöytisk preparat inneholdende disse
NO975987D0 (no) 4-Fenylaminotiazol-derivater, fremgangsmåte for fremstilling av disse og farmasöytiske blandinger inneholdende nevnte derivater
NO20001409D0 (no) Karboksamidotiazolderivater, fremgangsmåte for fremstilling derav og farmasøytiske blandinger
DK1156049T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
NO307707B1 (no) Spiroazabicykliske forbindelser, farmasøytisk preparat inneholdende slike forbindelser og anvendelse derav
NO307827B1 (no) Benzoksazol- og pyridinderivater, anvendelse av dem og farmasøytisk preparat inneholdende dem
NO981817D0 (no) Indolin-2-on-derivater, fremgangsmÕte for fremstilling av dem og farmas÷ytiske blandinger inneholdende dem
NO961006L (no) Fosfonomononukleinsyrer, fremgangsmåter for fremstilling derav og anvendelse av forbindelsene
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
GB9520584D0 (en) Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
HUP9602635A2 (en) 4-aciloxy-benzenesulfonamide derivatives, process for their preparation and pharmaceutical compositions containing them
NO950537L (no) Polysubstituerte 3-acylamino-5-fenyl-1,4-benzodiazepin-2-on-derivater, fremgangsmåter for fremstilling derav og farmasöytiske blandinger inneholdende dem
EE9900112A (et) 2-tsüanoiminoimidasooli derivaadid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
NO961000D0 (no) Piperidinderivater, fremgangsmåte for fremstilling derav og medikament og preparat inneholdende slike
HUP9901485A2 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
IL117495A0 (en) Beta-alanine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
NO975076D0 (no) Farmasöytisk preparat som inneholder tiagabinhydroklorid, og fremgangsmåte for dets fremstilling
FI960316A0 (fi) Oksatiolaanit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
NO955320L (no) Substituerte 4-fenyltiazolderivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger som inneholder dem
EE03996B1 (et) Farmatseutilised kompositsioonid, nende valmistamismeetod ja kasutamine
NO970136D0 (no) Granulös formulering inneholder mikroorganismer, fremgangsmåte for fremstilling og anvendelse derav
DK0806949T3 (da) Ny farmaceutisk komposition, der indeholder trimebutin, og fremgangsmåde til fremstilling deraf
DK1100775T3 (da) 2,5-Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til fremstilling deraf, anvendelse deraf og farmaceutiske præparater indeholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN OCTOBER 2003